Praxis Precision Medicines, Inc. SEC Filings

Cormorant Asset Management, LP and Bihua Chen report beneficial ownership of 1,625,000 shares of Praxis Precision Medicines common stock, representing 7.72% of the outstanding class. The shares are held through Cormorant-managed funds (the "Cormorant Funds") and the filing attributes voting and dispositive authority as shared rather than sole power.

The filing notes that the Cormorant Funds have the economic rights to dividends or sale proceeds and identifies Cormorant Global Healthcare Master Fund, LP as a fund with rights to more than 5% of the reported shares. The statement clarifies it is filed on behalf of both reporting persons and disclaims that the filing alone establishes beneficial ownership for purposes of Section 13.

This amendment to a Schedule 13G reports that Janus Henderson Group plc and an affiliated fund hold material stakes in Praxis Precision Medicines common stock. The filing shows Janus Henderson Group plc beneficially owns 2,533,405 shares, representing 12.4% of the class, with shared voting and dispositive power over those shares. Janus Henderson Biotech Innovation Master Fund Ltd is reported to beneficially own 1,186,586 shares ( 5.8% ).

The filing identifies indirect subsidiaries (JHIUS, JHIUKL and JHIAIFML) as registered investment advisers and includes a certification that the securities were acquired in the ordinary course of business and not for the purpose of changing or influencing control. A power of attorney authorizes certain compliance officers to file and amend reporting documents on behalf of Janus Henderson.

Adage Capital Management, L.P., together with Robert Atchinson and Phillip Gross, report beneficial ownership of 1,974,585 shares of Praxis Precision Medicines common stock, representing 9.69% of the outstanding class. The shares are directly held by Adage Capital Partners, L.P. and the percentage is calculated using an aggregate of 20,368,982 shares outstanding as reported by the company.

The filing shows shared voting and shared dispositive power for the reporting persons and no sole voting or dispositive power. It also certifies the securities are held in the ordinary course of business and were not acquired to change or influence control of the issuer. Reporting entities are organized in Delaware and the named individuals are U.S. citizens.

Perceptive Advisors LLC, its Perceptive Life Sciences Master Fund, Ltd. and founder Joseph Edelman have filed a Schedule 13G disclosing a passive stake in Praxis Precision Medicines (PRAX).

• Shares owned: 1,362,503 common shares.
• Ownership percentage: 6.69 % of the 20,368,982 shares outstanding as of 30 Apr 2025.
• Control rights: The Reporting Persons hold shared voting and dispositive power over all shares; they report zero sole voting/dispositive power, indicating no unilateral control.
• Date of event: 15 Jul 2025; filing signed 22 Jul 2025.
• Filer status: Perceptive Advisors is an investment adviser (IA); Edelman is a U.S. individual; Master Fund is Cayman-based.

The certification states the securities were not acquired to influence control, confirming a passive investment posture. Perceptive’s >5 % position may draw investor attention because the healthcare-focused fund is considered a sophisticated life-sciences investor.

Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing that director Dean J. Mitchell received a new stock option grant for 10,520 common shares on 26 June 2025. The option carries an exercise price of $44.04 and expires on 26 June 2035. Vesting occurs in twelve equal monthly installments over one year starting on the grant date. No common shares were bought or sold; this is purely an equity-based compensation award that increases Mr. Mitchell’s derivative holdings to 10,520 options, all held directly. The transaction is routine and designed to align director incentives with shareholder interests, with minimal immediate balance-sheet or ownership impact on PRAX.

Praxis Precision Medicines (PRAX) – Form 4 Insider Activity

Director William D. Young disclosed the grant of a stock option for 10,520 common shares on 26-Jun-2025 at an exercise price of $44.04. The option vests in twelve equal monthly installments over one year, beginning on the grant date, and expires on 26-Jun-2035. No open-market purchases or sales of common stock were reported. Following the transaction, Mr. Young beneficially owns 10,520 derivative securities linked to PRAX common shares. The filing was executed on 27-Jun-2025.